Deadline Looms for CureVac Shareholders in BioNTech Takeover

The window for CureVac shareholders to accept a pivotal takeover bid is closing rapidly. The offer from BioNTech SE is set to expire at 3:00 PM Central European Time on Tuesday, December 3rd. This final countdown arrives amid significant market volatility for the acquiring company, casting a shadow over the transaction's immediate value.

The structure of this all-stock deal is central to current investor concerns. CureVac shareholders are set to receive BioNTech shares in exchange for their holdings. The value of that consideration has come under pressure following a sharp decline in BioNTech's stock price. On Monday, BioNTech shares fell to €85.20, a drop triggered by regulatory commentary in the United States.

The sell-off was ignited after FDA representative Vinay Prasad suggested stricter authorization standards for future vaccine boosters, sending shockwaves through the mRNA sector. Competitor Moderna also faced selling pressure, and CureVac's stock was pulled lower in the downdraft.

By Tuesday morning in Frankfurt, CureVac shares were trading at €4.34, reflecting a decline of nearly three percent. On the Nasdaq the previous day, the stock had fallen 5.28 percent to $5.20. The direct correlation is clear: as BioNTech's share price falls, the implied value of the exchange offer for CureVac stockholders decreases proportionally.

Sector Jitters Overshadow Solid Fundamentals

This sector-wide uncertainty is poorly timed. Operationally, CureVac has recently demonstrated strength, reporting third-quarter revenues of €54.1 million and earnings per share of €1.21. The company's cash runway, extending into 2028, had been a key rationale for the strategic combination with BioNTech.

Should investors sell immediately? Or is it worth buying CureVac?

Despite the recent weakness, CureVac's equity has posted a gain of over 52 percent since the start of the year. The critical question for shareholders now is whether BioNTech can stabilize before the transaction is finalized, or if further depreciation awaits.

Final Decision Point for Shareholders

With the acceptance deadline imminent, CureVac investors face a binary choice. Those who do not tender their shares by the Tuesday afternoon cutoff will remain as minority shareholders in the company post-acquisition, awaiting a potential subsequent squeeze-out procedure.

CureVac's current market capitalization stands at approximately €1.01 billion. Over the past 52 weeks, its share price has fluctuated between a low of €2.00 and a high of €4.90.

The takeover itself has already received overwhelming shareholder approval, with 99.16 percent of votes cast in favor, and has cleared antitrust authorities. Nevertheless, the final hours before the offer closes are being dominated by external market forces rather than the deal's fundamental terms.